Middle East & Africa Precision Oncology Market Size & Outlook
Middle East Africa Precision Oncology Market, 2018-2030 (US$M)
Global Market
Related Markets
MEA precision oncology market highlights
- The MEA precision oncology market generated a revenue of USD 3,569.1 million in 2024.
- The market is expected to grow at a CAGR of 3.5% from 2025 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2024.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2025 to 2030.
MEA data book summary
| Market revenue in 2024 | USD 3,569.1 million |
| Market revenue in 2030 | USD 4,454.2 million |
| Growth rate | 3.5% (CAGR from 2025 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Diagnostics |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | Thermo Fisher Scientific Inc, Invitae Corp, Qiagen NV, Illumina Inc, Exact Sciences Corp, Rain Oncology, Strata Oncology, Xilis, Variantyx, BioServe, Relay Therapeutics, Acrivon Therapeutics |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.1% of the global precision oncology market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 50,287.5 million by 2030.
The precision oncology market in the Middle East and Africa is expected to grow at the fastest CAGR during the forecast period, due to several driving factors. Increasing availability of innovative cancer therapies through strategic collaborations contributes to the region’s growth. For instance, in November 2024, Pharmaceuticals entered into a collaboration with Pharmalink. With this partnership, Pharmalink received the commercial rights for sugemalimab, an advanced anti-cancer therapy, across key countries in the MENA region and South Africa.
This agreement not only ensures the supply and commercialization of sugemalimab but also accelerates access to cutting-edge treatments in countries like Saudi Arabia, UAE, Egypt, and South Africa. Such collaborations are bolstering the precision oncology ecosystem by addressing unmet medical needs and improving cancer care outcomes across the region.
No credit card required*
Publish Date: Jan 22, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Precision Oncology Market Scope
Precision Oncology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Exact Sciences Corp | View profile | 6,600 | 5505 Endeavor Lane, Madison, WI, United States, 53719 | www.exactsciences.com |
| Invitae Corp | View profile | 1,700 | 1400 16th Street, San Francisco, CA, United States, 94103 | www.invitae.com |
| Rain Oncology | View profile | 101-250 | Newark, California, United States, North America | www.rainoncology.com |
| Strata Oncology | View profile | 51-100 | Ann Arbor, Michigan, United States, North America | www.strataoncology.com/ |
| Xilis | View profile | 51-100 | Durham, North Carolina, United States, North America | www.xilis.net |
| Variantyx | View profile | 101-250 | Framingham, Massachusetts, United States, North America | www.variantyx.com |
| BioServe | View profile | 51-100 | Beltsville, Maryland, United States, North America | bioserve.com |
Middle East & Africa Precision Oncology Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Precision Oncology Market Outlook will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 74.54% in 2024.
Horizon Databook has segmented the Middle East & Africa precision oncology market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The precision oncology market in the Middle East and Africa is expected to grow at the fastest CAGR during the forecast period, due to several driving factors. Increasing availability of innovative cancer therapies through strategic collaborations contributes to the region’s growth. For instance, in November 2024, Pharmaceuticals entered into a collaboration with Pharmalink. With this partnership, Pharmalink received the commercial rights for sugemalimab, an advanced anti-cancer therapy, across key countries in the MENA region and South Africa.
This agreement not only ensures the supply and commercialization of sugemalimab but also accelerates access to cutting-edge treatments in countries like Saudi Arabia, UAE, Egypt, and South Africa. Such collaborations are bolstering the precision oncology ecosystem by addressing unmet medical needs and improving cancer care outcomes across the region.
- Middle East & Africa Precision Oncology Market Product Outlook (Revenue, USD Million , 2018-2030)
- Diagnostics
- Therapeutics
- Middle East & Africa Precision Oncology Market Cancer Outlook (Revenue, USD Million , 2018-2030)
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Prostate Cancer
- Lung Cancer
- Others
- Middle East & Africa Precision Oncology Market End Use Outlook (Revenue, USD Million , 2018-2030)
- Hospitals & Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Healthcare Data Companies
Reasons to subscribe to Precision Oncology Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Precision Oncology Market Outlook databook
- Our clientele includes a mix of Precision Oncology Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Precision Oncology Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Precision Oncology Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Middle East Africa Precision Oncology Market, 2018-2030 (US$M)
MEA Product - Precision Oncology Market Statistics, 2024 - 2030 (US$M)
